Cytokinetics EVP Fady Malik sells $214,830 in company stock

Cytokinetics' Executive Vice President of Research & Development, Fady Malik, sold 3,500 shares of the company's common stock on October 6, 2026, for a total of $214,830. The shares were sold at $61.38 per share, slightly under the current price of $62.91. This transaction left Malik with a remaining holding of 153,902 shares. Analysts maintain a "strong buy" consensus for Cytokinetics, with price targets ranging from $85 to $146, despite the company's unprofitable status over the past year.

On the same day, Malik also exercised non-qualified stock options, purchasing 3,500 shares at $7.8 per share, totaling $27,300. This brings his current non-qualified stock options to 19,886. Cytokinetics recently reported strong sales of its drug Myqorzo at $25.3 million for the second quarter, exceeding analyst estimates. The company has also filed a lawsuit against Bristol-Myers Squibb and MyoKardia over patent infringement concerns for MYQORZO.